Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.

Hanafusa N, Isoai A, Ishihara T, Inoue T, Ishitani K, Utsugisawa T, Yamaka T, Ito T, Sugiyama H, Arakawa A, Yamada Y, Itano Y, Onodera H, Kobayashi R, Torii N, Numata T, Kashiwabara T, Matsuno Y, Kato M.

PLoS One. 2017 May 16;12(5):e0177303. doi: 10.1371/journal.pone.0177303. eCollection 2017.

2.

Erythrocyte glutathione is a novel biomarker of Diamond-Blackfan anemia.

Utsugisawa T, Uchiyama T, Toki T, Ogura H, Aoki T, Hamaguchi I, Ishiguro A, Ohara A, Kojima S, Ohga S, Ito E, Kanno H.

Blood Cells Mol Dis. 2016 Jul;59:31-6. doi: 10.1016/j.bcmd.2016.03.007. Epub 2016 Apr 11.

PMID:
27282564
3.

ATP11C is a major flippase in human erythrocytes and its defect causes congenital hemolytic anemia.

Arashiki N, Takakuwa Y, Mohandas N, Hale J, Yoshida K, Ogura H, Utsugisawa T, Ohga S, Miyano S, Ogawa S, Kojima S, Kanno H.

Haematologica. 2016 May;101(5):559-65. doi: 10.3324/haematol.2016.142273. Epub 2016 Mar 4.

4.

Ribosomal protein S19 deficiency leads to reduced proliferation and increased apoptosis but does not affect terminal erythroid differentiation in a cell line model of Diamond-Blackfan anemia.

Miyake K, Utsugisawa T, Flygare J, Kiefer T, Hamaguchi I, Richter J, Karlsson S.

Stem Cells. 2008 Feb;26(2):323-9. Epub 2007 Oct 25.

5.

Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency.

Kanno H, Utsugisawa T, Aizawa S, Koizumi T, Aisaki K, Hamada T, Ogura H, Fujii H.

Haematologica. 2007 Jun;92(6):731-7.

6.

Smad7 promotes self-renewal of hematopoietic stem cells.

Blank U, Karlsson G, Moody JL, Utsugisawa T, Magnusson M, Singbrant S, Larsson J, Karlsson S.

Blood. 2006 Dec 15;108(13):4246-54. Epub 2006 Aug 17.

7.

Erythropoiesis in the Rps19 disrupted mouse: Analysis of erythropoietin response and biochemical markers for Diamond-Blackfan anemia.

Matsson H, Davey EJ, Fröjmark AS, Miyake K, Utsugisawa T, Flygare J, Zahou E, Byman I, Landin B, Ronquist G, Karlsson S, Dahl N.

Blood Cells Mol Dis. 2006 Mar-Apr;36(2):259-64. Epub 2006 Feb 7.

PMID:
16458028
8.

A road map toward defining the role of Smad signaling in hematopoietic stem cells.

Utsugisawa T, Moody JL, Aspling M, Nilsson E, Carlsson L, Karlsson S.

Stem Cells. 2006 Apr;24(4):1128-36. Epub 2005 Dec 15.

9.

Candesartan prevents angiotensin II-induced facilitation of hypoxic neuronal damage through PKCdelta inhibition.

Utsugisawa K, Nagane Y, Utsugisawa T, Obara D, Terayama Y.

Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):134-40. Epub 2005 Jan 22.

PMID:
15857676
10.

Development of cellular models for ribosomal protein S19 (RPS19)-deficient diamond-blackfan anemia using inducible expression of siRNA against RPS19.

Miyake K, Flygare J, Kiefer T, Utsugisawa T, Richter J, Ma Z, Wiznerowicz M, Trono D, Karlsson S.

Mol Ther. 2005 Apr;11(4):627-37.

11.

Deficiency of ribosomal protein S19 in CD34+ cells generated by siRNA blocks erythroid development and mimics defects seen in Diamond-Blackfan anemia.

Flygare J, Kiefer T, Miyake K, Utsugisawa T, Hamaguchi I, Da Costa L, Richter J, Davey EJ, Matsson H, Dahl N, Wiznerowicz M, Trono D, Karlsson S.

Blood. 2005 Jun 15;105(12):4627-34. Epub 2004 Dec 30.

12.

Short consensus probes with 3'-minor groove binder of the immunoglobulin heavy-chain gene for real-time quantitative PCR in B-cell non-Hodgkin lymphomas.

Uchiyama M, Maesawa C, Yashima-Abo A, Tarusawa M, Satoh M, Satoh T, Ishida Y, Ito S, Murai K, Enomoto S, Utsugisawa T, Masuda T.

Lab Invest. 2004 Jul;84(7):932-6.

13.

Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas.

Uchiyama M, Maesawa C, Yashima A, Tarusawa M, Satoh T, Ishida Y, Ito S, Murai K, Enomoto S, Utsugisawa T, Motoyoshi K, Masuda T.

Cancer Sci. 2003 Oct;94(10):877-85.

14.

Quantitative assessment of contaminating tumor cells in autologous peripheral blood stem cells of B-cell non-Hodgkin lymphomas using immunoglobulin heavy chain gene allele-specific oligonucleotide real-time quantitative-polymerase chain reaction.

Yashima A, Maesawa C, Uchiyama M, Tarusawa M, Satoh T, Satoh M, Enomoto S, Sugawara K, Numaoka H, Murai K, Utsugisawa T, Ishida Y, Masuda T.

Leuk Res. 2003 Oct;27(10):925-34.

PMID:
12860013
15.

Clonal evolution of blasts in an elderly patient with CD56(+) relapsed acute promyelocytic leukemia.

Itoh S, Sugawara T, Enomoto S, Ono Y, Numaoka H, Utsugisawa T, Murai K, Ishida Y, Kuriya S.

Am J Hematol. 2002 Jan;69(1):59-63.

PMID:
11835333
16.

Function for p300 and not CBP in the apoptotic response to DNA damage.

Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Shi Y, Weichselbaum R, Kufe D.

Oncogene. 1999 Oct 7;18(41):5714-7.

17.

Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage.

Huang Y, Nakada S, Ishiko T, Utsugisawa T, Datta R, Kharbanda S, Yoshida K, Talanian RV, Weichselbaum R, Kufe D, Yuan ZM.

Mol Cell Biol. 1999 Apr;19(4):2986-97.

18.

Role for p300 in stabilization of p53 in the response to DNA damage.

Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y, Kufe D.

J Biol Chem. 1999 Jan 22;274(4):1883-6.

19.

Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation.

Yuan ZM, Utsugisawa T, Ishiko T, Nakada S, Huang Y, Kharbanda S, Weichselbaum R, Kufe D.

Oncogene. 1998 Apr 2;16(13):1643-8.

20.

Regulation of Rad51 function by c-Abl in response to DNA damage.

Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S, Wang R, Sung P, Shinohara A, Weichselbaum R, Kufe D.

J Biol Chem. 1998 Feb 13;273(7):3799-802.

21.

Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine.

Huang Y, Yuan ZM, Ishiko T, Nakada S, Utsugisawa T, Kato T, Kharbanda S, Kufe DW.

Oncogene. 1997 Oct 16;15(16):1947-52.

22.

Inhibition of phosphatidylinositol 3-kinase by c-Abl in the genotoxic stress response.

Yuan ZM, Utsugisawa T, Huang Y, Ishiko T, Nakada S, Kharbanda S, Weichselbaum R, Kufe D.

J Biol Chem. 1997 Sep 19;272(38):23485-8.

23.

Role for E2F in DNA damage-induced entry of cells into S phase.

Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kato T, Yuan ZM.

Cancer Res. 1997 Sep 1;57(17):3640-3.

24.

[Early establishment of bone marrow hypoplasia by antileukemic chemotherapy with concurrent rhG-CSF in a case of acute myelogenous leukemia complicated with intestinal perforation].

Ono Y, Ito S, Murai K, Miyairi Y, Enomoto S, Kaneko J, Sugawara T, Numaoka H, Shimosegawa K, Utsugisawa T, Narigasawa Y, Ito T, Ishida Y, Kuriya S.

Rinsho Ketsueki. 1997 Jan;38(1):41-6. Japanese.

PMID:
9028160
25.

A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.

Kuriya S, Murai K, Miyairi Y, Utsugisawa T, Narigasawa Y, Ito T, Shimosegawa K, Ishida Y.

Cancer. 1996 Aug 1;78(3):422-6.

PMID:
8697386
26.

[Interleukin-3 therapy in patients with aplastic anemia refractory to prior therapies].

Miyairi Y, Murai K, Utsugisawa T, Narigasawa Y, Ito S, Shimosegawa K, Sugawara T, Numaoka H, Ono Y, Ito T, Ishida Y, Kuriya S.

Rinsho Ketsueki. 1996 Jan;37(1):22-8. Japanese.

PMID:
8683863
27.

[Hematological stability under ubenimex monotherapy in a patient with acute myelogenous leukemia developing marrow karyotypic changes during the course].

Shimosegawa K, Ono Y, Sugawara T, Numaoka H, Oikawa H, Ito S, Utsugisawa T, Murai K, Narigasawa Y, Miyairi Y, et al.

Rinsho Ketsueki. 1995 Nov;36(11):1289-94. Japanese.

PMID:
8691570
28.

[Morphological observation of a process of bone marrow hypoplastic formation in a case of aplastic anemia].

Utsugisawa T, Ono Y, Sugawara T, Numaoka H, Shimosegawa K, Ito S, Murai K, Narigasawa Y, Miyairi Y, Ito T, et al.

Rinsho Ketsueki. 1995 Oct;36(10):1157-62. Japanese.

PMID:
8531324
29.

Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia.

Oikawa H, Utsugisawa T, Murai K, Narigasawa Y, Miyairi Y, Shimosegawa K, Suzuki T, Kuriya S.

Int J Hematol. 1995 Jun;61(4):229-30. No abstract available.

PMID:
8547613
30.

[Initiation of hematopoietic recovery by recombinant human granulocyte-macrophage colony-stimulating factor in a case of severe aplastic anemia induced by gold salt].

Murai K, Michimata M, Shimosegawa K, Oikawa H, Utsugisawa T, Narigasawa Y, Miyairi Y, Kuriya S.

Rinsho Ketsueki. 1995 Jan;36(1):23-8. Japanese.

PMID:
7715074
31.

[Indications of G-CSF in patients with drug-induced agranulocytosis].

Takeda R, Utsugisawa T, Murai K, Narigasawa Y, Miyairi Y, Kuriya S.

Rinsho Ketsueki. 1993 Sep;34(9):997-1001. Japanese.

PMID:
7693988
32.

[Long-term maintenance of platelets by IFN alpha-2b in a case of chronic idiopathic thrombocytopenic purpura refractory to prednisolone therapy].

Murai K, Hirano H, Utsugisawa T, Takeda R, Narigasawa Y, Kanazawa T, Miyairi Y, Kuriya S.

Rinsho Ketsueki. 1993 Feb;34(2):207-11. Japanese.

PMID:
8492419

Supplemental Content

Loading ...
Support Center